Christian Kölln1, Stephan Reichl. 1. Institut für Pharmazeutische Technologie, Technische Universität Braunschweig, Braunschweig, Germany.
Abstract
PURPOSE: Drugs from ophthalmic formulations are mainly absorbed into the eye via the corneal route. However, little is known about drug metabolism during the transcorneal passage. The objective of this study was to determine the mRNA expression of phase I and II isoenzymes in human corneal epithelial tissue, corneal cell lines, and a tissue-engineered cornea equivalent (a hemicornea construct) as in vitro model for drug absorption studies. METHODS: The reverse transcription polymerase chain reaction was used to profile the mRNA expression of 10 cytochrome P450 enzymes (CYP) and seven phase II enzymes in the three human corneal cell lines and the hemicornea construct. The human corneal epithelial cell line (HCE-T), human corneal keratocyte cell line (HCK-Ca) and human corneal endothelial cell line (HENC) were used. Human liver tissue, human corneal epithelium from donor corneas, and the human colon adenocarcinoma cell line Caco-2 were also investigated. RESULTS: All the phase I and II mRNAs were expressed in the human liver tissue. The Caco-2 cell line showed an expression pattern similar to the liver tissue, although the signals for CYP1A2 and CYP3A4 were absent. In the case of the donor human corneal epithelium, all the detected phase I mRNAs had lower levels than did the liver tissue. By contrast, the phase II mRNA expression pattern was heterogeneous to the liver tissue. The expression patterns in the three human corneal cell lines were comparable, although the signals for a few phase I enzymes and N-acetyltransferase (NAT2) mRNAs were only detectable in the HCE-T. In the hemicornea construct, all the investigated phase I and II mRNA (except for CYP1A2, CYP2B6, CYP2C19, and NAT2) were expressed. CONCLUSIONS: Overall, the mRNA expressions of the tested phase I and phase II enzymes in the hemicornea construct and the three corneal cell lines correlated well with the expression patterns of the ex vivo human corneal epithelium.
PURPOSE: Drugs from ophthalmic formulations are mainly absorbed into the eye via the corneal route. However, little is known about drug metabolism during the transcorneal passage. The objective of this study was to determine the mRNA expression of phase I and II isoenzymes in human corneal epithelial tissue, corneal cell lines, and a tissue-engineered cornea equivalent (a hemicornea construct) as in vitro model for drug absorption studies. METHODS: The reverse transcription polymerase chain reaction was used to profile the mRNA expression of 10 cytochrome P450 enzymes (CYP) and seven phase II enzymes in the three human corneal cell lines and the hemicornea construct. The human corneal epithelial cell line (HCE-T), human corneal keratocyte cell line (HCK-Ca) and human corneal endothelial cell line (HENC) were used. Human liver tissue, human corneal epithelium from donor corneas, and the humancolon adenocarcinoma cell line Caco-2 were also investigated. RESULTS: All the phase I and II mRNAs were expressed in the human liver tissue. The Caco-2 cell line showed an expression pattern similar to the liver tissue, although the signals for CYP1A2 and CYP3A4 were absent. In the case of the donorhuman corneal epithelium, all the detected phase I mRNAs had lower levels than did the liver tissue. By contrast, the phase II mRNA expression pattern was heterogeneous to the liver tissue. The expression patterns in the three human corneal cell lines were comparable, although the signals for a few phase I enzymes and N-acetyltransferase (NAT2) mRNAs were only detectable in the HCE-T. In the hemicornea construct, all the investigated phase I and II mRNA (except for CYP1A2, CYP2B6, CYP2C19, and NAT2) were expressed. CONCLUSIONS: Overall, the mRNA expressions of the tested phase I and phase II enzymes in the hemicornea construct and the three corneal cell lines correlated well with the expression patterns of the ex vivo human corneal epithelium.
Authors: Cathie D Xiang; Minerva Batugo; David C Gale; Tao Zhang; Jingjing Ye; Chunze Li; Sue Zhou; Ellen Y Wu; Eric Y Zhang Journal: Drug Metab Dispos Date: 2009-02-12 Impact factor: 3.922
Authors: Marjo Volotinen; Jukka Mäenpää; Hannu Kautiainen; Ari Tolonen; Jouko Uusitalo; Auli Ropo; Heikki Vapaatalo; Esko Aine Journal: Eur J Pharm Sci Date: 2008-11-01 Impact factor: 4.384
Authors: Tao Zhang; Cathie D Xiang; David Gale; Samantha Carreiro; Ellen Y Wu; Eric Y Zhang Journal: Drug Metab Dispos Date: 2008-04-14 Impact factor: 3.922
Authors: Marcus Gry; Rebecca Rimini; Sara Strömberg; Anna Asplund; Fredrik Pontén; Mathias Uhlén; Peter Nilsson Journal: BMC Genomics Date: 2009-08-07 Impact factor: 3.969
Authors: Dimitrios Karamichos; Paulina Escandon; Brenda Vasini; Sarah E Nicholas; Lyly Van; Deanna H Dang; Rebecca L Cunningham; Kamran M Riaz Journal: Prog Retin Eye Res Date: 2021-11-02 Impact factor: 19.704
Authors: Alexander Vaneev; Victoria Tikhomirova; Natalia Chesnokova; Ekaterina Popova; Olga Beznos; Olga Kost; Natalia Klyachko Journal: Int J Mol Sci Date: 2021-11-16 Impact factor: 5.923
Authors: Seppo Rönkkö; Kati-Sisko Vellonen; Kristiina Järvinen; Elisa Toropainen; Arto Urtti Journal: Drug Deliv Transl Res Date: 2016-12 Impact factor: 4.617